Anna Nijdam Sells 2,670 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Anna Nijdam sold 2,670 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $30.87, for a total transaction of $82,422.90. Following the sale, the insider directly owned 46,275 shares in the company, valued at $1,428,509.25. This represents a 5.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Anna Nijdam also recently made the following trade(s):

• On Thursday, May 21st, Anna Nijdam sold 1,829 shares of Pharvaris stock. The stock was sold at an average price of $30.60, for a total value of $55,967.40.
• On Friday, May 22nd, Anna Nijdam sold 5,501 shares of Pharvaris stock. The stock was sold at an average price of $30.74, for a total value of $169,100.74.

Pharvaris Stock Up 2.0%

PHVS stock traded up $0.62 during midday trading on Monday, reaching $31.71. 388,815 shares of the company’s stock traded hands, compared to its average volume of 240,184. The company has a 50-day simple moving average of $29.24 and a two-hundred day simple moving average of $27.32. Pharvaris N.V. has a 1-year low of $16.00 and a 1-year high of $33.33. The company has a market cap of $2.07 billion, a price-to-earnings ratio of -9.97 and a beta of -2.35.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.12. Equities research analysts forecast that Pharvaris N.V. will post -3.22 EPS for the current year.

Analyst Ratings Changes

PHVS has been the subject of a number of research analyst reports. Wolfe Research assumed coverage on shares of Pharvaris in a research note on Thursday, April 9th. They issued an “outperform” rating and a $42.00 target price for the company. Citizens Jmp lowered their price target on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a report on Wednesday, May 13th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price objective on shares of Pharvaris in a report on Tuesday, March 3rd. Wall Street Zen raised Pharvaris from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, UBS Group set a $74.00 target price on Pharvaris in a research report on Wednesday, May 13th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $49.18.

Hedge Funds Weigh In On Pharvaris

A number of hedge funds and other institutional investors have recently made changes to their positions in PHVS. General Atlantic L.P. raised its stake in Pharvaris by 6.6% during the 3rd quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock worth $200,380,000 after buying an additional 500,000 shares during the period. Foresite Capital Management IV LLC increased its holdings in shares of Pharvaris by 8.3% in the third quarter. Foresite Capital Management IV LLC now owns 4,778,581 shares of the company’s stock worth $119,226,000 after acquiring an additional 368,000 shares in the last quarter. venBio Partners LLC raised its position in shares of Pharvaris by 8.2% during the third quarter. venBio Partners LLC now owns 4,639,304 shares of the company’s stock worth $115,751,000 after purchasing an additional 350,000 shares during the period. Deerfield Management Company L.P. lifted its holdings in shares of Pharvaris by 21.1% during the 3rd quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company’s stock valued at $60,939,000 after purchasing an additional 425,000 shares in the last quarter. Finally, Commodore Capital LP raised its holdings in shares of Pharvaris by 26.5% during the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after acquiring an additional 507,043 shares during the period.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.